Sleep Apnea and Lung Cancer

Prognostic Significance of Sleep Apnea in Non Small Cell Lung Cancer

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03741647

Enrollment

Registered

2018-11-15

Start date

2018-11-15

Completion date

2021-02-28

Last updated

2019-12-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Locally Advanced Non Small Cell Lung Cancer

Brief summary

cases of locally advanced non small cell lung cancer (diagnosed by PET/CT scan and histopathological confirmation) will be screened for sleep disorders by Epworth sleepiness scale then confirmed by full night polysomnographic study. Blood sample to detect some genetic determinants will be withdrawn

Interventions

DIAGNOSTIC_TESTsleep study and blood sample

full night polysomnographic study and blood sample to detect some genetic issues

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* patients with locally advanced non small cell lung cancer

Exclusion criteria

* unable or refuse to perform sleep study * metastatic cases

Design outcomes

Primary

Measure	Time frame	Description
assessment Response to treatment	6 weeks from ending therapy	CT chest/pelvi-abdomen with contrast (evaluation using RECIST criteria)
confirmed Response to treatment	4 weeks from assessment response	CT chest/pelvi-abdomen with contrast (evaluation using RECIST criteria)

Secondary

Measure	Time frame	Description
Progression Free Survival	3 months from confirmed response to treatment	CT chest/pelvi-abdomen with contrast (evaluation using RECIST criteria)
Overall survival	3 months after enrollment	regular patient follow up visit

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026